ClinicalTrials.gg
Status unknownNCT03486561MIDAUpdated Apr 3, 2018

Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)

A Phase 4 interventional study of Ranolazine in Chronic Stable Angina, sponsored by OBS Pakistan. Status unknown. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-04-03.

Sponsored by OBS Pakistan · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,000
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The rationale of MIDA trial is to determine efficacy and tolerability of ranolazine molecule among Pakistan population and obtain firsthand knowledge about the molecule ranolazine.

02

Conditions studied

  • Chronic Stable Angina

Keywords

  • Ranolazine
  • Pakistan
  • Ischemic Heart Disease
03

In context

Angina, Stable

344 studies on the registry are indexed under Angina, Stable; 57 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 150 across 231 interventional studies indexed under Angina, Stable.

Browse Angina, Stable studies →

Lead sponsor

OBS Pakistan is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with diagnosis of coronary artery disease (CAD)

    • Patients present with the symptoms of stable angina after withdrawn from other antianginal drugs and given the required background therapy for at least 7 days will be qualified for entering this study and performing 1st ETT qualifying test
    • Patients developed exercise-induced ischemiai during two qualifying exercise treadmill testsii.
    • Willing and able to provide a written

Exclusion criteria

Exclusion Criteria:

    • Factors that might compromise or ETT interpretation

      • Patients with resting ST-segment depression ≥ 1mm in any lead
      • Left bundle-branch block
      • Patients implanted with pacemaker
      • Patients under Digitalis therapy

        • Patients with family history of (or congenital) long syndrome
        • Patients with congenital heart disease
        • Patients with uncorrected valvular heart disease
        • Patients with unstable angina, or MI, or coronary revascularization procedure ≤ 2 months prior enter this study
        • Female who is pregnant/lactating or planning to be pregnant, or female of * who is not using medically recognized method of
      • *Other than those who have been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year .

        • Patients are under any one of the following conditions:
      • (NYHA) Class III or Class IV congestive heart failure (CHF)
      • QTc > 450 msec at screening
      • Active myocarditis, pericarditis, hypertrophic cardiomyopathy
      • Uncontrolled hypertension (defined as SBP > 180 mmHg) Voltage criteria for left ventricular hypertrophy in the absence of repolarization abnormalities will not be exclusion criteria

        • Use of any product ≤ 4 weeks prior to screening
        • Patients with severe hepatic disease (e.g., liver cirrhosis)
        • Patients with impaired renal function (defined as serum Cr >1.5 mg/dl)
        • Patients with any condition or disease which is considered not suitable for this study by investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Other
    Ranolazine

    Ranolazine was approved by the U.S. Food and Drug Administration in 2006 in 500 mg and 1000 mg extended-release doses, advising 500 mg BID as a starting dose and 1000 mg BID as maximum dose

    Drug: Ranolazine

Interventions

  • Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.

06

What researchers measure

Primary outcomes

  1. Efficacy: Reduction in frequency of Angina with Ranolazine

    To determine reduction in frequency of Angina with Ranolazine

    Time frame: 24 weeks

Secondary outcomes

  1. Safety: Proportion of participants experiencing an adverse event (AE)

    Proportion of participants experiencing an adverse event (AE)

    Time frame: 24 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2018; primary completion for Sep 2018, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2018
First posted
Apr 3, 2018
StartEst.
Apr 1, 2018
Primary completionEst.
Sep 30, 2018
CompletionEst.
Oct 31, 2018
Last update
Apr 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03486561
Lead sponsor
OBS Pakistan
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
Apr 1, 2018 (estimated)
Primary completion
Sep 30, 2018 (estimated)
Completion
Oct 31, 2018 (estimated)
Last update
Apr 3, 2018

Study contacts

Faizan Shaukat
Contact
faizan.shaukat@obs.com.pk
+923328814816

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion